Here's Why Nvidia Caused BNP Paribas to Downgrade Arista Networks Stock (ANET)
Shares of Arista Networks (ANET) are down at the time of writing after the cloud networking firm was downgraded by BNP Paribas. In fact, 4.5-star analyst Karl Ackerman lowered his rating on the stock from Outperform to Neutral due to increasing competitive pressure from Nvidia (NVDA) and low-cost whitebox vendors like Celestica (CLS) and Accton. These new threats could take market share away from Arista in the AI networking space.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Ackerman explained that the AI networking market is shifting quickly from Ethernet to InfiniBand, with Nvidia and other companies positioned to dominate this segment. Indeed, Nvidia's upcoming Quantum-X switches, which are expected to support 1.6T speeds and launch in the second half of 2025 — about a year ahead of comparable Ethernet products — may significantly limit Arista's near-term growth opportunities.
In addition, the move toward rack-scale GPU architectures is accelerating this shift, thereby giving Nvidia and other players an advantage when it comes to capturing the bulk of the Ethernet switching market. As a result of these competitive pressures, Ackerman revised his outlook for Arista's AI-related revenue. He now expects the company to generate $2.5 billion in AI sales by 2027, which is down significantly from his previous forecast of $3.4 billion.
Is ANET Stock a Good Buy?
Turning to Wall Street, analysts have a Moderate Buy consensus rating on ANET stock based on 11 Buys, four Holds, and zero Sells assigned in the past three months, as indicated by the graphic below. Furthermore, the average ANET price target of $109.38 per share implies 17% upside potential.
See more ANET analyst ratings
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
28 minutes ago
- Globe and Mail
Analysts Offer Insights on Healthcare Companies: Zai Lab (ZLAB), LifeMD (LFMD) and Novo Nordisk (NVO)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Zai Lab (ZLAB – Research Report), LifeMD (LFMD – Research Report) and Novo Nordisk (NVO – Research Report). Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Zai Lab (ZLAB) Bank of America Securities analyst David Li maintained a Hold rating on Zai Lab today and set a price target of $38.20. The company's shares closed last Tuesday at $37.22, close to its 52-week high of $39.77. Li has an average return of 17.5% when recommending Zai Lab. ;'> According to Li is ranked #6632 out of 9628 analysts. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zai Lab with a $53.04 average price target. LifeMD (LFMD) In a report released today, David Larsen from BTIG maintained a Buy rating on LifeMD, with a price target of $18.00. The company's shares closed last Tuesday at $13.58. According to Larsen is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -10.1% and a 29.7% success rate. Larsen covers the Healthcare sector, focusing on stocks such as Definitive Healthcare Corp, P3 Health Partners, and Oncology Institute. ;'> LifeMD has an analyst consensus of Strong Buy, with a price target consensus of $12.00. Novo Nordisk (NVO) TD Cowen analyst Michael Nedelcovych maintained a Buy rating on Novo Nordisk today and set a price target of $105.00. The company's shares closed last Tuesday at $74.34, close to its 52-week low of $69.18. According to Nedelcovych is ranked 0 out of 5 stars with an average return of -12.6% and a 33.3% success rate. Nedelcovych covers the Healthcare sector, focusing on stocks such as Takeda Pharmaceutical Company, Bausch Health Companies, and Molecular Partners AG. ;'> Novo Nordisk has an analyst consensus of Hold, with a price target consensus of $92.71.
Globe and Mail
29 minutes ago
- Globe and Mail
AI is Top of Mind in Alithya's 2025 Industry Trends Reports for Manufacturing, Healthcare, and Financial Services
ALPHARETTA, Ga., June 19, 2025 /CNW/ - Alithya Group, inc. (TSX: ALYA) ("Alithya") today announced the release of its 2025 Industry Trends Reports and Analysis across three critical sectors: manufacturing, healthcare, and financial services. Each report is based on a survey of industry professionals and offers exclusive insights into the key trends, challenges, and opportunities expected to shape business conditions in the next 12 months.
Globe and Mail
29 minutes ago
- Globe and Mail
Dynacor Group Reports Sales of US$26.1 Million in May 2025
MONTREAL, June 19, 2025 (GLOBE NEWSWIRE) -- Dynacor Group Inc. (TSX-DNG) ('Dynacor' or the "Corporation"), today announced unaudited gold sales of $26.1 million in May and year-to-date sales of $128.9 million. All figures are in US dollars unless otherwise indicated. Monthly Highlights Gold sales reached $26.1 million (C$36.2 million 1) in May 2025, compared to $23.7 million (C$32.4 million) in May 2024. The increase in sales of $2.4 million or +10.1% versus May 2024 results from an increase in the sales price (+32.1%) partially offset by a decrease in volume (-21.9%) that in part results from planned plant maintenance. In May, the selling price of gold averaged $3,293 per ounce, compared to $2,340 per ounce, a 40.7% increase over May 2024. Year To Date Highlights Cumulative gold sales reached $128.9 million at the end of May 2025, compared to $116.4 million for the same period of 2024, a $12.5 million increase or +10.7%. In 2025, the selling price of gold averaged $3,015 per ounce, compared to $2,178 per ounce in 2024, a 38.4% increase. The Corporation is on target to meet its annual sales guidance of between $345 and $375 million. About Dynacor Dynacor Group is an industrial ore processing company dedicated to producing gold sourced from artisanal miners. Since its establishment in 1996, Dynacor has pioneered a responsible mineral supply chain with stringent traceability and audit standards for the fast-growing artisanal mining industry. By focusing on fully and part-formalized miners, the Canadian company offers a win-win approach for governments and miners globally. Dynacor operates the Veta Dorada plant and owns a gold exploration property in Peru. The Corporation plans to expand to West Africa and within Latin America. The premium paid by luxury jewellers for Dynacor's PX Impact® gold goes to Fidamar Foundation, an NGO that mainly invests in health and education projects for artisanal mining communities in Peru. Visit for more information. Forward-Looking Information Certain statements in the preceding may constitute forward-looking statements, which involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance, or achievements of Dynacor, or industry results, to be materially different from any future result, performance or achievement expressed or implied by such forward-looking statements. These statements reflect management's current expectations regarding future events and operating performance as of the date of this news release. Contact: For more information, please contact: Ruth Hanna Director, Investor Relations T: 514-393-9000 #236 E: investors@ Website: Renmark Financial Communications Inc. Bettina Filippone T: (416) 644-2020 or (212) 812-7680 E: bfilippone@ Website: 1 Sales are converted using the average monthly exchange rate.
